Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Getting Organized for GDUFA: FDA Elevates Generic Review Activities Under New Director Geba

This article was originally published in RPM Report

Executive Summary

In the two months since the enactment of the Generic Drug User Fee Act, FDA has announced a major recruitment from the brand sector to head its generic drug activities (Gregory Geba), approved one controversial transdermal generic (Watson’s lidocaine topical patch), and elevated the generic review activities to “Super Office” status.

You may also be interested in...



FDA’s Woodcock to Head Office of Pharmaceutical Quality; New Details Emerge

FDA’s proposed Office of Pharmaceutical Quality will be initially headed by CDER Director Janet Woodcock. OPQ would hold responsibility over the manufacturing quality of a drug or biologics throughout a product’s lifecycle; eight offices will oversee activities from policy development to surveillance.

Growing Pains for Generic Drugs: OGD Gains Respect, But Loses Geba

FDA’s Office of Generic Drugs was at the start of a turnaround: $299 million in new user fees to clear a big ANDA backlog and fund overseas inspections, an elevated status within the Center for Drugs and a brand-new director to steer the ship. But there have been some bumps in GDUFA implementation, and OGD’s new director, Gregory Geba, has abruptly left the agency. What next for FDA’s generic drug oversight?

GDUFA Implementation Will Be Overseen By Mylan’s Representative in the House

Mylan played a pivotal role in crafting the formula to create Generic Drug User Fees. The selection of Rep. Tim Murphy (R-Pa.) to chair the House Energy & Commerce Oversight Subcommittee should help assure that Mylan’s perspectives continue to play an important role.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS081038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel